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Abstract
Background: miR-15a and miR-16-1(miR-15a/16-1) have been implicated as tumor suppressors in chronic
lymphocytic leukemia, multiple myeloma, and acute myeloid leukemic cells. However the mechanism of inhibiting
the proliferation of leukemic cells is poorly understood.
Methods: K562 and HL-60 cells were transfected with pRS-15/16 or pRS-E, cell growth were measured by CCK-8
assay and direct cell count. Meanwhile WT1 protein and mRNA level were measured by Western blotting and
quantitative real-time PCR.
Results: In this study we found that over-expression of miR-15a/16-1 significantly inhibited K562 and HL-60 cells
proliferation. Enforced expression of miR-15a/16-1 in K562 and HL-60 cells significantly reduced the protein level of
WT1 but not affected the mRNA level. However enforced expression of miR-15a/16-1 can not reduce the activity of
a luciferase reporter carrying the 3’-untranslated region(3’UTR) of WT1. Silencing of WT1 by specific siRNA
suppressed leukemic cells proliferation resembling that of miR-15a/16-1 over-expression. Anti-miR-15a/16-1
oligonucleotides (AMO) reversed the expression of WT1 in K562 and HL-60 cells. Finally, we found a significant
inverse correlation between miR-15a or miR-16-1 expression and WT1 protein levels in primary acute myeloid
leukemia (AML) blasts and normal controls.
Conclusions: These data suggest that miR-15a/16-1 may function as a tumor suppressor to regulate leukemic cell
proliferation potentially by down-regulating the WT1 oncogene. However WT1 is not directly targeted by miR-15a/
16-1 through miRNA-mRNA base pairing, therefore more study are required to understand the mechanism by
which miR-15a/16-1 downregulate WT1.
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Introduction
MicroRNAs (miRNAs) are non-coding regulatory RNAs
of 21 to 25 nucleotides and regulate most of basal pro-
gress such as cell proliferation, survival, apoptosis, and
differentiation by triggering either translational repres-
sion or mRNA degradation [1-3]. Recently an increasing
number of data have demonstrated that almost 50% of
miRNAs are located at or close to fragile sites of regions.
This regions are known to be amplified or deleted in
human cancer [4]. miRNAs may function as tumor sup-
pressor genes or potential oncogenes during the initiation
and progression of cancer [5]. The function of some miR-
NAs is dependent upon the specific cell type. On one
hand miR-221 and miR-222 act as oncogenes in solid
tumors, on the other hand the same miRNAs function as
tumor suppressors in erythroblastic leukemia cells [6]. In
animals, single-stranded miRNA binds specific mRNA
through sequences that are imperfectly complementary
to the target mRNA, mainly to the 3’ untranslated region
(UTR). The bound mRNA can be degraded, resulting in
decreased level of the corresponding mRNA or remains
untranslated, resulting in decreased level of the corre-
sponding protein [1,7].
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reside at a genomic region of chromosome 13q14.3, which
frequently was deleted or down-regulated in the majority
of chronic lymphocytic leukemia (CLL), and in a subset of
mantle cell lymphomas [8]. Calin et al. demonstrated that
in MEG-01 cells enforced expression of miR-15a/16-1
inhibited cell proliferation and induce apoptosis through
targeting multiple oncogenes such as Bcl-2, WNT3A,
MCL1, and CCND1 in vitro and in vivo [9,10]. However
the mechanism of inhibiting the proliferation of leukemic
cells is still not clear.
The Wilms’ tumor gene (WT1) locating at the short
arm of chromosome 11 regulates the expression of differ-
ent genes like transforming growth factor beta, Bcl-2,
and human telomerase reverse transcriptase [11-13].
High levels of WT1 which are detected in most cases of
acute myelogeous leukemia and chronic myelogeous leu-
kemia (CML) in blast crisis are associated with a worse
long-time prognosis [14]. WT1 is firstly thought to func-
tion as tumor suppressor, but the following wildly studies
support that WT1 act as oncogene [15].
In this study we reported that miR-15a/16-1 were able
to significantly suppress K562 and HL-60 cells prolifera-
tion through down-regulating WT1 protein level. Either
down-regulation of WT1 by siRNA significantly inhibited
the proliferation of leukemic cells. Thus, these data sug-
gest that miR-15a/16-1 may function as a tumor suppres-
sor to influence the proliferation of leukemic cells through
down-regulating WT1 protein level. However, enforced
expression of miR-15a/16-1 can not reduce the activity of
a luciferase reporter carrying the 3’-untranslated region
(3’UTR) of WT1. This result means that miR-15a/16-1
down-regulated the expression of WT1 not through
miRNA-mRNA base pairing. Whether miR-15a/16-1
downregulate other genes which interact with WT1 is not
decided. Therefore more study are required to shed light
of the new mechanism, which will open new avenues in
understanding the mechanisms of miRNA action.
Materials and methods
cell lines and primary leukemic cells
K562 and HL-60 cell lines were employed for the present
study. All cells were cultured in RPMI 1640 supplemented
with 10% fetal bovine serum (Invitrogen, Groud Island,
USA) in humidified 37°C incubator with 5% CO2. Primary
AML cells were obtained from 20 patients with AML (2
M1 5 M2, 5 M3, 2 M4, 6 M5, the First Affiliated Hospital
of Wenzhou Medical College). None of these patients had
received any treatment. The diagnosis was established
according to French-American-British classification. All
patients gave informed consent in accordance with the
Declaration of Helsinki for cryopreservation and use of the
samples for molecular studies.
RNA extraction
Bone marrow mononuclear cells from normal individuals
and patients with AML were aspirated by Ficoll density
gradient centrifugation (GE Healthcare, Uppsala, Sweden).
Total RNA from cultured cell lines and bone marrow
mononuclear cells were extracted by TRIzol (Invitrogen)
Following the manufacture’s protocol. RNA concentra-
tions and quality were determined with Beckman DU6400
spectrophotometer (Beckman, USA) and gel analysis.
qPCR for miRNA and mRNA expression
Quantitative real-time polymerase chain reaction (qRT-
PCR) analysis for miR-15a and miR-16-1 was performed
in triplicate with the NCode™ miRNA First-strand cDNA
synthesis and SYBR
® Green PCR Master Mix (Applied
Biosystems, Foster City, CA) according to the manufac-
turer’s instructions. U6 snRNAs was used as the internal
control. The fold-change for miR-15a/16-1 expression
levels was calculated using ΔCT and 2
-ΔΔCT.W T 1t r a n -
script was determined by quantitative real-time PCR using
specific primer sets [16] and ABL housekeeping gene was
used for normalization [17]. The following primers were
used respectively, WT1: (sense strand: 5’-CAG GCT GCA
ATA AGA GAT ATT TTA AG CT-3’, antisense strand:
5’-GAA GTC ACA CTG GTA TGG TTT CTC A-3’,T a q -
man probe: 5’-Fam-CTT ACA GAT GCA CAG CAG
GAA GCA CAC TGA-Tamra-3’), ABL: (sense strand: 5’-
GAT GTA GTT GCT TGG GAC CCA-3’,a n t i s e n s e
strand: 5’-TGG AGA TAA CAC TCT AAG CAT AAC
TAA AGG T-3’,T a q m a np r o b e :5 ’-Fam-CCA TTT TTG
GTT TGG GCT TCA CAC CAT T-Tamra-3’).
Plasmids Transfection
pRETROSUPER vector expressing miR-15a/16-1 (pRS-
15/16) was constructed as previously described [10,18].
The same empty plasmid (pRS-E) was served as control.
Leukemic cells were transiently transfected with 1 μg/mL
(final concentration) pRS-E or pRS-15/16 vector using
Lipofectamine™ LTX and PLUS™ Reagents (Invitrogen)
according to the manufacturer’s instructions.
Cell counting kit-8 (CCK-8) assay and trypan-blue
exclusion assay
The mock or transfected K562, HL-60 and U937 cells
were seeded into 96-well plates (6.0 × 10
3 cells/well). Cell
viability was assessed by CCK-8 assay (Dojin Labora-
tories, Kumamoto, Japan). The absorbance at 450 nm
(A450) of each well was read on a spectrophotometer.
Three independent experiments were performed in quad-
ruplicate. Alternatively, cell viability was determined by
the trypan-blue exclusion assay, and growth inhibition
rate was calculated according to viable cell numbers of
treated cells against numbers of untransfected cells.
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transfection
SiRNA sequences targeting WT1 (National Center for
Biotechnology Information accession number AH003034)
were synthesized. siRNA-WT1: ccauaccagugugacuuca cor-
responds to positions 9-27 of exon 7 within the WT1 cod-
ing sequence [19]. SiRNA-WT1 and unspecific control
siRNA (N.C) were obtained from Invitrogen. SiRNA-WT1
and N.C were transfected into K562 and HL-60 cells by
the aid of Hiperfect transfection reagent (Qiagen, Valencia,
USA). The sequences of anti-miR-15a/16-1 oligonucleo-
tide (AMO) were designed according to the principle of
sequences complementary to mature miR-15a and miR-
16-1. AMO and scramble (SCR) were chemically synthe-
sized by Qiagen. AMO and SCR (final concentration of 50
nM) were transfected into K562 and HL-60 cells mediated
by Hiperfect transfection reagent (Qiagen).
Western blotting
Bone marrow mononuclear cells from normal individuals
and patients with AML were aspirated by Ficoll density
gradient centrifugation (GE Healthcare). Protein extracts
from cell lines, normal individuals and patient samples
prepared with RIPA lysis buffer (50 mM TrisHCl,
150 mM NaCl, 0.1% SDS, 1% NP-40, 0.5% sodiumdeoxy-
cholate, 1 mM PMSF, 100 mM leupeptin, and 2 mg/mL
aprotinin, pH 8.0) were separated on an 8% SDS-polyacry-
lamide gel and transferred to nitrocellulose membranes.
After blocking with 5% nonfat milk, the membranes were
incubated with an appropriate dilution (WT1 1:2000) of
the primary antibody (Abcom, Cambridge, MA, USA), fol-
lowed by incubation with the horseradish peroxidase
(HRP)-conjugated secondary antibody (abcom) according
to manufacturer’s instructions. The signals were detected
by chemiluminescence phototope-HRP kit (Cell Signaling,
Danvers, MA, USA) according to manufacturer’s instruc-
tions. As necessary, blots were stripped and reprobed with
anti-GAPDH antibody (Abcom) as an internal control. All
experiments were repeated three times with the similar
results. Signal intensity of proteins was normalized against
GAPDH using Quantity One (Bio-Rad).
Luciferase reporter experiments
The 3’UTR segments from the WT1 and Bcl-2 gene were
amplified by PCR from cDNA and inserted into the pGL3
control vector (Promega), using the XbaΙ site immediately
downstream from the stop codon of luciferase. Bcl-2 is
one of known targeted gene by miR-15a/16-1 [9]. The fol-
lowing primer set was used to generate specific fragments:
Bcl-2UTRF, 5’-CTA GTC TAG AGC CTC AGG GAA
CAG AAT GAT CAG-3’; Bcl-2UTRR, 5’-CTA GTC TAG
AAA GCG TCC ACG TTC TTC ATT G-3’ [9].
WT1UTRF, 5’-CTA GTC TAG GTA GAC CCA AAG
GTC CTT AAG TT-3’;W T 1 U T R R ,5 ’-CTA GTC TAG
G A TA C CG G TG C TT C TG G AA - 3 ’. The cells were
cotransfected in 24 well plate using Lipofectamine™ LTX
and PLUS™ Reagents (Invitrogen) according to the manu-
facturer’s protocol using 0.1 ug of the firefly luciferase
report vector and 0.1 ug of the control vector pRL-TK
(Promega, WI, USA) containing Renilla luciferase. For
each well 0.5 ug pRS-15/16 or negative control pRS-E
were used. Firefly and Renilla luciferase activities were
measured by dual luciferase reporter assay (Promega) after
transfection. Firefly luciferase activity was normalized to
Renilla luciferase activity.
Statistical Analysis
The significance of the difference between groups was
determined by Student’s t-test. A P value of less than .05
was considered statistically significant. Relationships
between miR-15a/16-1 and WT1 expression were
explored by Pearson’s correlation coefficient. All statistical
analyses were performed with SPSS software (version 13).
Results
miR-15a/16-1 suppress the proliferation of K562 and HL-
60 cells
In order to explore the functional role of miR-15a/16-1 in
leukemic cells, we examined the effect of miR-15a/16-1
over-expression on the proliferation of K562 and HL-60
cell lines. The cells were transfected with either pRS-15/16
or negative control plasmid (pRS-E) for 24, 48, and 72 h.
The qRT-PCR analysis confirmed that the expression of
miR-15a and miR-16-1 was obviously increased in cells
transfected wth pRS-15/16 compared with negative con-
trol (Figure 1A and 1B). CCK-8 assay and direct cell count
showed that over-expression of miR-15a/16-1 significantly
inhibited the proliferation of both K562 (*P < 0.05, Figure
1C and 1D) and HL-60 cells (*P < 0.05, Figure 1E and 1F).
In a word, our data indicate that miR-15a/16-1 may play
an important role in the proliferation of leukemic cells in
vitro.
miR-15a/16-1 reduce WT1 protein level not through
targeting mRNAs according to the degree of
complementarity with their 3’UTR
Calin et al. showed that WT1 was a target of miR-15a/
16-1 in MEG-01 cells by microarray and proteomics ana-
lysis [10]. However whether WT1 was directly targeted
by miR-15a/16-1 in K562 and HL-60 cells was not veri-
fied in lab. As indicated in Figure 2A, over-expression of
miR-15a/16-1 in K562 and HL-60 cells obviously reduced
the protein level of WT1 at 24 and 48 h after transfection
with pRS-15/16 compared with normal controls, whereas
the level of WT1 mRNA was not significantly affected
(Figure 2B). Then we cloned the 3’UTR region of WT1
downstream of a luciferase reporter gene and corre-
sponding negative control into K562 and HL-60 cells, but
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was not significantly decreased compared with the nega-
tive control (Figure 2C and 2D). Bcl-2 is a target of post-
transcriptional repression by miR-15 and miR-16-1,
which act as a positive control [9].
Anti-miR-15a/16-1 oligonucleotides (AMO) reversed the
expression of WT1 in K562 and HL-60 cells
In order to investigate the effect of AMO-miR-15a/16-
1 on WT1 expression, we transfected AMO-miR-15a/
16-1 to K562 and HL-60 cells for 24 and 48 h. miR-
15a/16-1 and U6 snRNA expression was determined
by quantitative real-time PCR. U6 snRNAs were used
as the internal control. The fold-change for miR-15a/
16-1 expression level was calculated using ΔCT and
2
-ΔΔCT, as described in the Materials and methods. As
indicated in Figure 3A and 3B, AMO effectively
decreased the expression of miR-15a/16-1 in K562 and
HL-60 cells. Meanwhile the protein level of WT1 was
increased but the mRNA level of WT1 was not
affected by AMO-miR-15a/16-1 at 48 hours compared
with control group (SCR) in K562 and HL-60 cells
(Figure 3C and 3D).
WT1 is involved in the regulation of cell proliferation by
miR-15a/16-1
Because miR-15a/16-1 inhibit leukemic cells proliferation
and suppress WT1 protein expression, we are interested
in examining whether miR-15/16-1 play a role in the regu-
lation of cell proliferation via WT1 regulation. To examine
the functional role of WT1 in leukemic cell proliferation,
we used siRNA specific for WT1. WT1 mRNA and pro-
tein levels were estimated by quantitative real-time PCR
and Western blotting individually. WT1 siRNA-treated
K562 and HL-60 cells showed a significant reduction of
WT1 mRNA level after 24 and 48 h as compared to k562
Figure 1 Effects of miR-15a/16-1 on the proliferation of K562 and HL-60 cells. K562 and HL-60 cells were transfected with pRS-15/16 or
pRS-E vector (negative control) for 24, 48 and 72 hours, then the relative expressions of miR-15a/16-1 were measured by qRT-PCR (A and B).
CCK-8 assay (C and E) and direct cell count (D and F) were performed when K562 and HL-60 cells were transfected with pRS-15/16 or pRS-E
vector at different time periods. Data are shown as mean ± SD from three independent experiments. *P < 0.05 versus negative control.
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of WT1 in k562 and HL-60 achieved up to 64% and 68%
respectively at 48 hours after siRNA transfection. Further-
more the reduction of mRNA using siRNA resulted in an
obvious decrease of WT1 protein level after 48 h in K562
and HL-60 cell lines (Figure 4B). Finally we observed that
the growth rates of k562 and HL-60 cells were significantly
reduced by siRNA-WT1 compared with negative control
through CCK-8 assay (Figure 4C and 4D), which resem-
bling that of miR-15a/16-1 over-expression.
The levels of miR-15a/16-1 are inversely correlated with
WT1 protein expression in leukemic cells
Finally we checked for the existence of a correlation
between the expression levels of miR-15a or miR-16-1
by qRT-PCR and the WT1 protein levels by Western
blotting in 25 AML samples and 5 normal controls. As
Figure 5A indicated, whereas in two normal control
cells the levels of both miRNAs were high and the WT1
protein was expressed at low levels, in six leukemic cells
both miR-15a and miR-16-1 were expressed at low
levels and WT1 was highly ex p r e s s e d .T oa s s e s st h e
clinical relevance of these findings, we correlated WT1
protein level with miR-15a/16-1 expression in 25 AML
samples and 5 normal controls. As indicated in Figure
5B and 5C, When WT1 protein levels were plotted
against that of miR-15a/16-1 in each normal control
and AML samples, a significant inverse correlation was
found (miR-15a verse WT1 R = -0.73 P < 0.01; miR-16-
1v e r s eW T 1R=- 0 . 7 6P < 0.01). These data indicate
that miR-15a/16-1 are inversely correlated with WT1
protein level in leukemic cells.
Discussion
Although miRNA signatures for leukemic cell have been
established, elucidation of the role of miRNAs in leuke-
mogenesis remains in the early stage of development
[20]. Calin and others presented that miR-15a/16-1 act
Figure 2 miR-15a/16-1 downregulates WT1 protein level not through targeting mRNAs according to the degree of complementarity
with their 3’UTR. (A) K562 and HL-60 cells were transiently transfected with pRS-15/16 or pRS-E vector for different time periods and subjected
to western analysis with the indicated antibodies. The level of GAPDH was used as a loading control. (B) K562 and HL-60 cells were transfected
with pRS-15/16 or pRS-E vector for 24 and 48 hours, then the relative expression of WT1 was measured by quantitative real-time PCR. (C and D).
K562 and HL-60 cells were transfected with the pGL-3 containing Bcl-2 3’UTR or WT1 3’UTR and pRS-15/16 or pRS-E for 24 hours, relative
repression fold of firefly luciferase expression was standardized to Renilla luciferase, pGL-TK.
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engraftments of leukemic cells in nude mice in vivo
[10]. Furthermore using microarray and proteomics ana-
lysis, they found miR-15a/16-1 exerted antileukemic
effect by targeting Bcl-2, WT1, and PDCD4 [10]. We
used PicTar, TargetScan, and MiRanda, the most widely
used algorithms for the identification of miRNA targets,
to predict the target of miR-15a/16-1. To our surprise
we could not find WT1 as the predicted target of miR-
15a/16-1. Then we cloned the 3’UTR region of WT1
downstream of a luciferase reporter gene and corre-
sponding negative control into K562 and HL-60 cells,
but the luciferase activity of cells transfected with pRS-
15/16 was not significantly decreased compared with the
negative control. This data indicate miR-15a/16-1 regu-
late WT1 protein expression not through targeting
mRNAs according to the degree of complementarity
with their 3’UTR. miR-15a/16-1 might regulate gene
transcription by a different mechanism than RNA-
induced silencing complex mediated protein translation
inhibition and/or mRNA cleavage.
Our understanding of the mechanisms by which miR-
NAs mediate their effects probably reflects a tip of the
iceberg. Eiring et al. demonstrated that the interaction
between miR-328 and poly(rC)-binding protein hnRNP
E2 is independent of the microRNA’ss e e ds e q u e n c e
[21]. They also revealed the dual ability of a microRNA
to control cell fate not only through base pairing with
mRNA targets but also through a decoy activity that
interferes with the function of regulatory proteins [21].
miRNAs also target the 5’UTR or the coding sequence
of mRNA and contribute to their down-regulation [22].
Jing et al. showed that AU-rich elements (AREs)
mediated instability was implicated in the regulation of
gene expression by miR-15a and miR-16-1 [23]. Given
that the interaction of miRNAs and their target genes is
complicated, more research is needed to decipher the
mechanisms by which miR-15a/16-1 down-regulate
WT1 protein level.
miR-15a/16-1 probably regulated the expression of
WT1 through an indirect effect on WT1. Several tran-
scription factors including GATA-1 and Sp1, which
bind to DNA consensus site at the proximal promoter
of the WT1 gene, can regulate the expression of WT1
[24,25]. We speculated whether GATA-1 and Sp1 were
the targets of miR-15a/16-1. We used PicTar, TargetS-
can, and MiRanda to predict whether GATA-1 and Sp1
were the targets of miR-15a/16-1. However we could
not find GATA-1 and Sp1 as the predicted targets of
miR-15a/16-1. Meanwhile GATA-1 and Sp1 protein
levels were not decreased by Western blotting after
K562 cell was transfected by miR-15a/16-1 (data not
Figure 3 AMO-miR-15a/16-1 reversed the expression of WT1 in K562 and HL-60 cells (A) and (B) AMO inhibited the expression of miR-
15a/16-1. K562 and HL-60 cells were incubated with AMO-miR-15a/16-1 for 24 and 48 hours, then miR-15a/16-1 and U6 snRNA expression were
determined by quantitative real-time PCR. (C) and (D) K562 and HL-60 cells were incubated with AMO-miR-15a/16-1 for 48 h, then mRNA and
protein level of WT1 were detected by quantitative real-time PCR and Western blotting individually. *P < 0.01 versus SCR.
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the targets of miR-15a/16-1. Considering that many
transcription factors could regulate the expression of
WT1, more study are required to test the possibility
that WT1 was regulated by downstream targets of miR-
15a/16-1.
Overexpression of WT1 is known to modulate apop-
tosis by upregulation of Bcl-2 gene expression [12,26].
However Hewitt et al. founded that WT1 could sup-
press the Bcl-2 promoter in transient transfection assays
[27]. Murata et al. did not see significant changes in
Bcl-2 expression in the M1 cells which induced to
express WT1 (+Ex5/-KTS) [28]. These conflicting data
demonstrate that the function of WT1 is cell-type speci-
fic. Depending on the cell type being investigated, WT1
can either activate Bcl-2 and function as an oncogene or
suppress Bcl-2 and function as a tumor suppressor.
Although Bcl-2 is a known direct target by miR-15a/16-
1 [9], whether miR-15a/16-1 indirectly down-regulate
Bcl-2 expression through WT1 mediated down-regula-
tion of Bcl-2 is still not proved in lab.
Depending on the cell type, WT1 had either tumor-
promoting or tumor-suppressing function [29,30]. Over-
expression of WT1 in human prostate cancer cells
inhibited proliferation, but the expression of WT1 in
leukemic cells enhanced proliferation [31,32]. Further-
more in AML and chronic myeloid leukemia (CML)
patients high level of WT1 was associated with a worse
long time outcome and poor event-free survival [14,33].
Yamagami et al. demonstrated that loss of WT1 was
associated with decreased growth of the leukemic cells
and rapid induction of apoptosis, when endogenous
WT1 in highly expressing leukemic cell lines and pri-
mary AML samples was decreased by antisense oligonu-
cleotides and RNA interference [34,35]. Our data
showed down-regulation of WT1 by either miR-15a/16-
1 over-expression and specific siRNA significantly inhib-
ited the proliferation of leukemic cells. This data suggest
that WT1 plays an important role in leukemogenesis.
As WT1 is ordinary over-expressing in AML and CML
patients, targeting WT1 as possible tool against leuke-
mic cells provides a new therapeutic option for AML
Figure 4 The role of miR-15a/16-1 in the regulation of leukemic cell proliferation. (A) and (B) K562 and HL-60 cells were incubated with
1.5 ug siRNA-WT1, 1.5 ug N.C or neither of the above for 24 and 48 hours, then the relative expression of WT1 and the corresponding WT1
protein level were separately measured by quantitative real-time PCR and Western blotting. (C) and (D) K562 and HL-60 cells treated with siRNA
or N.C or neither of the above were measured by CCK-8 assay at different time periods. Data are shown as mean ± SD from three independent
experiments. *P < 0.05 versus negative control.
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siRNA against WT1 will have an effect in CML patients
because suppressing of WT1 expression in vitro was
associated with inhibition of BCR-ABL tyrosine kinase
activity [36].
Conclusion
Our data demonstrated for the first time that over-
expression of miR-15a/16-1 significantly inhibited K562
and HL-60 cells proliferation through down-regulating
WT1 protein level. However miR-15a/16-1 down-regu-
lated WT1 protein level not through targeting mRNAs
according to the degree of complementarity with their
3’UTR. The most important thing is to shed light on the
new mechanisms by which miRNA mediated their
effect, which will open new avenues for miRNA action.
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